DexCom, Inc.
DexCom designs, develops, and commercializes continuous glucose monitoring systems for people with diabetes and healthcare providers. Products include G6 and G7 CGM systems, Share remote monitoring, Real-Time API, and ONE device replacing finger stick testing. The company also submitted FDA review for Stelo for type 2 diabetes patients.
Overview
Strengths
- Creates economic value: ROIC of 34.8% against a cost of capital (WACC) of 9.1%, a spread of 25.7 percentage points.
- Resilient profitability: operating margin stayed between 11% and 20% in each of the last 6 years.
- Consistent growth: revenue has compounded at 19.3% a year over 5 years, rising every year.
- ROIC of 34.8% beats 98% of its 51 Medical Devices peers (median 9.6%).
- EBITDA margin of 29.1% beats 90% of its 51 Medical Devices peers (median 13.3%).
- Improving fundamentals over the last year: return on assets up 4.3 points and asset turnover up 18.2%.
Weaknesses
- Our discounted cash flow target price (51.84 USD) is 39% below the current price.
- Valued at a premium to its Medical Devices peers: EV/EBITDA 24.3x vs. a median of 16.2x.
Key Financial Data